2. Academic Validation
  3. FR-900098, an antimalarial development candidate that inhibits the non-mevalonate isoprenoid biosynthesis pathway, shows no evidence of acute toxicity and genotoxicity

FR-900098, an antimalarial development candidate that inhibits the non-mevalonate isoprenoid biosynthesis pathway, shows no evidence of acute toxicity and genotoxicity

  • Virulence. 2016 Aug 17;7(6):718-28. doi: 10.1080/21505594.2016.1195537.
Jochen Wiesner 1,  Christina Ziemann 2,  Martin Hintz 3,  Armin Reichenberg 4,  Regina Ortmann 4,  Martin Schlitzer 4,  Rainer Fuhst 2,  Nina Timmesfeld 5,  Andreas Vilcinskas 1 6,  Hassan Jomaa 7
Affiliations

Affiliations

  • 1 a Department of Bioresources , Fraunhofer Institute for Molecular Biology and Applied Ecology IME , Gießen , Germany.
  • 2 b Fraunhofer Institute for Toxicology and Experimental Medicine ITEM , Hannover , Germany.
  • 3 c Institut für Laboratoriumsmedizin und Pathobiochemie, Molekulare Diagnostik am Standort Gießen, Universitätsklinikum Gießen und Marburg GmbH , Gießen , Germany.
  • 4 d Institut für Pharmazeutische Chemie, Philipps-Universität Marburg , Marburg , Germany.
  • 5 e Institut für Medizinische Biometrie und Epidemiologie, Philipps-Universität Marburg , Marburg , Germany.
  • 6 f Institute for Insect Biotechnology, Justus-Liebig-University of Gießen , Gießen , Germany.
  • 7 g Institut für Laboratoriumsmedizin und Pathobiochemie, Molekulare Diagnostik am Standort Marburg, Universitätsklinikum Gießen und Marburg GmbH , Marburg , Germany.
PMID: 27260413 DOI: 10.1080/21505594.2016.1195537
Abstract

FR-900098 is an inhibitor of 1-deoxy-d-xylulose-5-phosphate (DXP) reductoisomerase, the second Enzyme in the non-mevalonate isoprenoid biosynthesis pathway. In previous studies, FR-900098 was shown to possess potent antimalarial activity in vitro and in a murine malaria model. In order to provide a basis for further preclinical and clinical development, we studied the acute toxicity and genotoxicity of FR-900098. We observed no acute toxicity in rats, i.e. there were no clinical signs of toxicity and no substance-related deaths after the administration of a single dose of 3000 mg/kg body weight orally or 400 mg/kg body weight intravenously. No mutagenic potential was detected in the Salmonella typhimurium reverse mutation assay (Ames test) or an in vitro mammalian cell gene mutation test using mouse lymphoma L5178Y/TK(+/-) cells (clone 3.7.2C), both with and without metabolic activation. In addition, FR-900098 demonstrated no clastogenic or aneugenic capability or significant adverse effects on blood formation in an in vivo micronucleus test with bone marrow erythrocytes from NMRI mice. We conclude that FR-900098 lacks acute toxicity and genotoxicity, supporting its further development as an antimalarial drug.

Keywords

Ames test; FR-900098; Plasmodium falciparum; acute toxicity; drug development; fosmidomycin; genotoxicity; malaria; micronucleus test; mouse lymphoma assay.

Figures
Products